Reduced TGFBR2 Expression in NSCLC Drives IL-17A Dependent Inflammation via γδT Cells

Nolan, Kathleen F.; Tippimanchai, D.; Verzosa, Grace C; Zhao, Wenjie; Li, H.; Phillip, Shaji; Malkoski, Stephen P.

doi:10.1016/j.jtho.2017.06.023

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The member of TGFb receptor family - TGFBR2 is a tumor suppressor in lung cancer, and the loss of TGFBR2 expression is associated with worse prognosis of both squamous cell cancer and adenocarcinoma ( 107 , 108 ). Accordingly, TGFBR2 mutation predicts lung cancer resistance to checkpoint inhibitors ( 121 ).…”

Section: Expression Of Molecules Involved In the Ctc Cluster Formatio...mentioning

confidence: 99%

Molecules promoting circulating clusters of cancer cells suggest novel therapeutic targets for treatment of metastatic cancers

Rozenberg

Buzdin²,

Mohammad³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Treatment of metastatic disease remains among the most challenging tasks in oncology. One of the early events that predicts a poor prognosis and precedes the development of metastasis is the occurrence of clusters of cancer cells in the blood flow. Moreover, the presence of heterogeneous clusters of cancerous and noncancerous cells in the circulation is even more dangerous. Review of pathological mechanisms and biological molecules directly involved in the formation and pathogenesis of the heterotypic circulating tumor cell (CTC) clusters revealed their common properties, which include increased adhesiveness, combined epithelial-mesenchymal phenotype, CTC-white blood cell interaction, and polyploidy. Several molecules involved in the heterotypic CTC interactions and their metastatic properties, including IL6R, CXCR4 and EPCAM, are targets of approved or experimental anticancer drugs. Accordingly, analysis of patient survival data from the published literature and public datasets revealed that the expression of several molecules affecting the formation of CTC clusters predicts patient survival in multiple cancer types. Thus, targeting of molecules involved in CTC heterotypic interactions might be a valuable strategy for the treatment of metastatic cancers.

show abstract

Section: Expression Of Molecules Involved In the Ctc Cluster Formatio...mentioning

confidence: 99%

Molecules promoting circulating clusters of cancer cells suggest novel therapeutic targets for treatment of metastatic cancers

Rozenberg

Buzdin²,

Mohammad³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Reduced TGFBR2 Expression in NSCLC Drives IL-17A Dependent Inflammation via γδT Cells

Cited by 1 publication

References 0 publications

Molecules promoting circulating clusters of cancer cells suggest novel therapeutic targets for treatment of metastatic cancers

Molecules promoting circulating clusters of cancer cells suggest novel therapeutic targets for treatment of metastatic cancers

Contact Info

Product

Resources

About